Comparative Pharmacology
Head-to-head clinical analysis: CROLOM versus CROMOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROLOM versus CROMOPTIC.
CROLOM vs CROMOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
Mast cell stabilizer that inhibits the release of histamine and other inflammatory mediators from mast cells. Also inhibits eosinophil chemotaxis and activation.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
1-2 drops in each eye 4 times daily for conjunctivitis; 1 drop in each eye 2-4 times daily for allergic conjunctivitis prophylaxis.
None Documented
None Documented
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
1.3 hours (terminal elimination half-life); clinically, due to rapid elimination, dosing is required 4 times daily for sustained effect.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours); the remainder is excreted in feces via biliary elimination (approximately 30%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer